CCCC
USDC4 Therapeutics Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$2.350
Kõrge
$2.420
Madal
$2.290
Maht
1.58M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
225.3M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
1.92M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Wells Fargo Maintains Overweight on C4 Therapeutics, Raises Price Target to $10
Wells Fargo analyst Derek Archila maintains C4 Therapeutics with a Overweight and raises the price target from $5 to $10.
Stephens & Co. Reiterates Overweight on C4 Therapeutics, Maintains $6 Price Target
Stephens & Co. analyst Sudan Loganathan reiterates C4 Therapeutics with a Overweight and maintains $6 price target.
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple
Barclays Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $8
Barclays analyst Etzer Darout initiates coverage on C4 Therapeutics with a Overweight rating and announces Price Target of $8.
Stephens & Co. Upgrades C4 Therapeutics to Overweight, Raises Price Target to $6
Stephens & Co. analyst Sudan Loganathan upgrades C4 Therapeutics from Equal-Weight to Overweight and raises the price target from $3 to $6.
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development...
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.